New York, New York (PRWEB) September 02, 2012
The shareholder committee's goal is to provide clarity and unite shareholders of Life Medical Technologies, Inc., in an effort to bring on board experienced medical industry and business professionals to move Life Medical Technologies forward and provide shareholders the transparency they deserve.
Save Life Medical Technologies committee head, Terence Herzog, filed a claim on July 6, 2012 against Life Medical Technologies, Inc., pursuant to Section 220 of the Delaware General Corporation Law to inspect books and records of Life Medical Technologies, Inc. This case, No. 7679, was filed in the Court of Chancery of the State of Delaware.
Concerned shareholders of Life Medical Technologies, Inc. should review the Save Life Medical Technologies website (http://www.savelmt.com).
For further information contact Terence Herzog at terenceherzogscac(at)gmail(dot)com.
According to Life Medical Technologies, Inc.’s, website (http://www.lifemt.com):
Life Medical Technologies is headquartered at the Hudson Valley Research Park, an IBM facility located in Fishkill, New York. The facility will also house manufacturing and distribution for BreastCare DTS™.
Life Medical Technologies believes that through the use of low-cost medical diagnostic testing and education of the benefits of early detection people worldwide can take greater control of their health. It’s initial focus is on the manufacture and sale of BreastCare DTS™, an easy-to-use device produced under patent which has been FDA-cleared as an adjunct to mammography and other procedures for the detection of breast disease, including breast cancer. They are committed to providing life-enhancing, innovative medical products to the public through partnerships with non-profit organizations, corporations, academia, the government, and individuals in an ongoing effort to bring about a successful outcome in the fight against breast cancer and other life-threatening illnesses.
BreastCare DTS™ is an easy-to-use device produced under patent which has been FDA-cleared as an adjunct to mammography and other procedures for the detection of breast disease, including breast cancer. BreastCare DTS™ has received FDA 510K clearance for marketing in the United States. Clinical studies have been conducted on over 5,000 women in prestigious cancer centers in the U.S., Europe and Latin America, including Memorial Sloan-Kettering in New York and M.D. Anderson in Houston, Texas. Results of clinical studies have included finding 87.5% of early stage tumors and attaining a very high degree of sensitivity and negative predictive value. Additionally, the studies have shown it to be particularly effective in detecting early tumors.